Physiological study of some hormonal parameters in infertile hyperprolactinemic women in pre and post-treatment with cabergoline and bromocriptine

Abstract EN

Hyperprolactinemia is the most common endocrine disorder.

It occurs more frequently in women than in men.

The clinical symptoms of hyperprolactinemia are amenorrhea, oligomenorrhea infertility, and galactorrhea in women ; decreased libido and impotence in men.

The aims of the study are to estimate some possible risk factors for hyperprolactinemic infertile women and to assess some hormonal and hematological changes to these women.

And also to reveal the role of two types of dopamine agonist drugs (cabergoline and bromocriptine) in treatment of hyperprolactinemia and restoring normal ovulation.

This study consists of a total number of 100 married women in the reproductive age(their age ranged between 18 and 42years), seventy women were in patient's groups and thirty healthy women were regarded as a control group.

Thirty five from seventy patients were given cabergoline and other thirty five of patients were given bromocriptine drug.

The results were obtained from the study found that most age group was 28-32 years.

The percentage of patients who had positive family history of hyperprolactinemia was significantly more than those in control group.

the percentage of patients and control who living in urban areas were significantly more than those living in rural areas.

In addition to that The percentage of patients who had primary infertility more than those who had secondary infertility.

Regarding the percentage of pre-treatment patients who had irregular menstrual cycle and galactorrhea, there was highly significant increase compared with control group and post- treatment patients while there was less significant decrease in patients after cabergoline drug therapy compared with patients treated with bromocriptine drug regarding the presence of these signs and symptoms.

Regarding hormonal assay, the study showed highly significant increase in serum prolactin hormone and testosterone hormone levels and high significant decrease in serum FSH, LH, and progesterone hormone levels in pre-treated patients compared with control group.

Furthermore; there was high significant decrease in serum prolactin hormone level, and less significant decrease in serum testosterone hormone level, and high significant increase in serum FSH, LH and progesterone hormone levels in post-treatment patients in compared with pre-treated patient's groups.

Additionally ; there was highly significant decrease in serum prolactin, low significant increase in LH and progesterone, and there was no significant difference in serum FSH and testosterone level in post- treated patients with cabergoline drug compared with post- treated patients with bromocriptine drug.

To conclude, hyperprolactinemia associated with increased and decreased in some hormonal parameters and the dopamine agonist agents are effective in correcting the disturbance in these parameters.